ProteinPaint gives researchers a free, interactive tool for advancing understanding of the mutations that lead to and drive pediatric cancer.
Tennessee Higher Education Commission unanimously approves
St. Jude graduate school in biomedical sciences.
Scientists discover how aggressive sarcoma lays the groundwork for cancer progression and chemotherapy resistance along with a possible solution.
St. Jude Red Frog Events Proton Therapy Center provides one of the most advanced radiation technologies yet for treatment of pediatric cancer.
St. Jude IOP will establish research goals to improve worldwide quality of care for children with cancer under Dr. Rodriguez-Galindo’s direction.
Gene variants identified that leave young acute lymphoblastic leukemia patients at increased risk for osteonecrosis as a side effect of treatment.
Small molecule drug discovery advances may aid hearing restoration by targeting an intrinsically disordered protein.
Pediatric Cancer Genome Project determines nearly one in ten of children with cancer have mutations in genes associated with cancer predisposition.
Three individuals from
St. Jude were recognized by the Memphis Business Journal for making a difference in their careers and the Memphis community.
An initiative has been launched to help advance the research of the dark proteome, proteins that control some cellular behavior.
For two generations of one family, inherited variation in the ETV6 gene linked to an increased risk of childhood acute lymphoblastic leukemia (ALL).
Barry Whyte is announced as new Vice President of Communications and Public Relations at
St. Jude Children’s Research Hospital.
Intensive, adaptive cognitive training presented as a video game was as effective as medication for improving the working memory of cancer survivors.
Scientists identify lead for reducing risk of respiratory distress in newborns born to women who develop intrahepatic cholestasis of pregnancy (ICP).
St. Jude study advances understanding of cellular organization and highlights a possible treatment strategy for degenerative diseases like ALS.
St. Jude scientists discover how mutations in the IKZF1 gene lead to high-risk leukemia and identify drugs that may help improve survival.
Researchers show how the most common genetic cause of ALS and a related disorder disrupts normal cell function, results offer hope for targeted therapies.
St. Jude Children’s Research Hospital has received designated Magnet status. Only 7 percent of all U.S. hospitals have received this designation.
Keith Perry has been named as
St. Jude chief information officer (CIO) to provide strategic counsel and leadership for the hospital’s information technology initiatives.
Jinghui Zhang, Ph.D., an international expert in the analysis of genomic data, will lead the growth of innovative effort in newly dedicated space supported by Brooks Brothers.
St. Jude scientists have discovered how the p53 protein works outside the cell nucleus to trigger cell death. The results could aid cancer therapy.
A subset of medulloblastoma tumors briefly stopped growing or disappeared during treatment with the targeted drug vismodegib.
St. Jude researchers have discovered a potential new method for determining whether masses in the chest cavity are a fungal infection or a tumor without performing a biopsy.
Roberts, an internationally recognized leader in cancer epigenetics, will oversee the country’s only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children.
St. Jude receive grants from the NIGMS for a Center for Precision Medicine in Leukemia to optimize curative treatments, translate genomics, and inform genomics methods for other disease treatments.
St. Jude scientists use new methods to show that one type of stem cell is superior to another for treating retinal degeneration in research that could advance such treatments
St. Jude Children's Research Hospital has ranked on Great Place to Work and Fortune's "100 Best Workplaces for Millennials" list.
St. Jude scientists created a second-generation of spectinomycin to combat bacteria that are a common cause of respiratory and other infections.
St. Jude discovery lays the foundation for developing new chemotherapy agents and finds evidence that statins slow growth of ependymoma tumor cells.
St. Jude discovered how an immune system protein called AIM2 plays a role in determining the aggressiveness of colon cancer.
Evidence from the Childhood Cancer Survivor Study (CCSS) suggests that changes in childhood cancer treatment have reduced deaths from the late effects of cancer treatment and extended the lives of childhood cancer survivors.
St. Jude Children’s Research Hospital investigators presented the research at the plenary session of the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).
J. Paul Taylor, M.D., Ph.D., of
St. Jude Children's Research Hospital, has been recognized as one of the nation’s leading biomedical researchers by the Howard Hughes Medical Institute.
Researchers have identified three genes that play a pivotal role in the brain tumor choroid plexus carcinoma (CPC), a discovery that lays the groundwork for more effective treatment of this rare, often fatal cancer.
Childhood cancer survivors – especially those whose treatment included brain irradiation or chemotherapy with glucocorticoids – are 14 percent more likely to be obese than their healthy peers.
St. Jude Children’s Research Hospital scientists show that mutations in the DDX3X gene lead to different molecular defects; findings will aid efforts to develop more individualized therapy of medulloblastoma.
Results of the
St. Jude Children’s Research Hospital-led study provide a target for developing novel therapies to tame the inflammation that drives autoinflammatory diseases.
St. Jude Children’s Research Hospital study lays the foundation for more effective treatment of childhood leukemia and a wide range of other disorders using small molecules to reverse glucocorticoid resistance
Addition extends access to clinical trials at
St. Jude to children beyond its physical walls through clinical, research and academic affiliations with medical centers in six states.
Study provides a target for developing novel therapies to tame the inflammation that drives autoinflammatory diseases
Richard Gilbertson, M.D., Ph.D., to become director of the Cambridge Cancer Centre in England.
St. Jude Children’s Research Hospital scientists have discovered major “switches” that activate the immune system to kill the bacterium, potentially leading to protective drugs and vaccines.
Investigators report measuring leukemia cells that persist in patient bone marrow in the early weeks of treatment helps identify high-risk patients.
Whole exome sequencing of 20 pediatric ALL patients yielded important insights into the genetic basis of ALL treatment failure. The findings may lead to early detection of the mutations that drive ALL relapse.
Thomas Merchant, D.O., Ph.D., to oversee radiotherapy programs for the treatment of childhood cancer.
St. Jude Children’s Research Hospital scientists identify key molecular events in pediatric adrenocortical tumors; findings could help clinicians identify most malignant subtypes and lead to better treatment.
St. Jude Children’s Research Hospital—Washington University Pediatric Cancer Genome Project study highlights need for targeted therapies against a rare infant leukemia with a poor prognosis. (James R. Downing, MD)
St. Jude Children’s Research Hospital has been recognized for the fifth year in a row as one of FORTUNE magazine’s “100 Best Companies to Work For.”
The genetic basis of three pediatric melanoma subtypes have been identified; findings could lead to better diagnosis and treatment.
Research could help reduce side effects associated with the anti-cancer drug vincristine.
Report suggests neutralizing a single protein may aid fight against a parasitic tropical disease.
Childhood cancer patients treated with cranial irradiation may have hormone deficiencies that impact health decades later.
Scientists have identified genetic variations associated with hearing loss in young cancer patients treated with cisplatin.
Thirumala-Devi Kanneganti, Ph.D., is recognized by the American Association of Immunologists for outstanding research contributions.
Scientists have linked inherited variations in a second gene to reduced tolerance of a key cancer drug.
Scientists show that the PTEN tumor suppressor protein is essential for proper regulatory T cell function.